Hengroi Pharma and Brave Heart Bio are presenting data from a 52-week open-label extension of the Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at the 2026 American Heart Association Scientific Meetings -. Company announcement - FT.